India accounts for 60% of head, neck cancer cases, figure to double by 2030

Owing to the increased use of tobacco, India contributes to nearly 60 per cent of head and neck cancer – inside the mouth, the nose, and the throat –patients worldwide and the number is expected to double by 2030, health experts said here on Saturday. “Tobacco is one of the major causes behind these cases of head and neck cancers. And we are estimating the number of cases to double by 2030,” added Sumit Goyal from Department of Medical Oncology at Rajiv Gandhi Cancer Institute in New Delhi.

In a clinical study, presented recently at the annual conference of American Society of Clinical Oncologists (ASCO), in Chicago, the experts led by Kumar Prabhash from Tata Memorial Hospital in Mumbai, concluded that a molecule called Nimotuzumab along with chemo-radiother- apy might be a better and effective treatment against head and neck cancers. Nimotuzumab is the first indigenously produced novel biologic developed by Bengaluru-based biotech major Biocon and introduced in India as BIOMAB EGFR for head and neck cancer in 2006.

To examine its efficacy, the clinical study examined 536 locally advanced head and neck cancer patients aged between 18 to 80 years. The results showed that patients who were administered Nimotuzumab combined with cisplatin drug –used for chemotherapy –and radiation, survived almost three times more than those who received only chemo and radiation. It also reduced the risk of disease progression by 26 per cent.

Biomab has a unique bivalent binding, because of which it binds primarily at the site of cancer cells where there is overexpression of the EGFR protein. This is significant since this mechanism of action of Biomab ensures that only the cancerous cells are destroyed, unlike other targeted agents, ensuring that it does not cause additional toxicity, said Prabhash.

The clinical study proved that the introduction of this molecule, to the existing standard of care in patients of head and neck cancer, dramatically improved treatment outcomes on factors like progression-free survival, disease-free survival, duration of loco-regional control and overall survival, he added.

Clinical study examined 536 locally advanced head and neck cancer patients aged between 18 to 80 years